Compare HHH & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HHH | LQDA |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | 500 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | 2023 | 2020 |
| Metric | HHH | LQDA |
|---|---|---|
| Price | $61.38 | $36.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $90.00 | $40.36 |
| AVG Volume (30 Days) | 543.2K | ★ 1.5M |
| Earning Date | 05-06-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $1,474,892,000.00 | $158,320,000.00 |
| Revenue This Year | $14.04 | $208.46 |
| Revenue Next Year | N/A | $27.44 |
| P/E Ratio | $28.05 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $61.41 | $11.26 |
| 52 Week High | $91.07 | $46.67 |
| Indicator | HHH | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 24.66 | 50.47 |
| Support Level | N/A | $30.48 |
| Resistance Level | $71.26 | $39.19 |
| Average True Range (ATR) | 1.68 | 2.14 |
| MACD | -0.31 | 0.34 |
| Stochastic Oscillator | 0.11 | 69.62 |
Howard Hughes Holdings Inc, through its subsidiary, operates a large-scale, mixed-use real estate platform focused on the development of master planned communities (MPCs), the investment in strategic real estate development opportunities, and the ownership and operation of income-producing properties. The group operates through three reportable business segments: Operating Assets, MPCs, and Strategic Developments. Maximum revenue is generated from the MPC segment, which consists of the development and sale of land in large-scale, long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. Revenues are mainly generated through the sale of residential and commercial land to homebuilders and developers.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.